查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018515

帕金森氏症深部腦部刺激市場：依技術、組件、最終用戶和分銷管道分類－2026-2032年全球市場預測

Deep Brain Stimulation in Parkinson's Disease Market by Technology, Component, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，帕金森氏症深部腦部刺激 (DSM) 市場價值將達到 14.1 億美元，到 2026 年將成長到 16.1 億美元，到 2032 年將達到 40.2 億美元，年複合成長率為 16.15%。

主要市場統計數據
基準年 2025 14.1億美元
預計年份：2026年 16.1億美元
預測年份 2032 40.2億美元
複合年成長率 (%) 16.15%

全面概述了神經調控、多學科臨床路徑和設備創新的進步如何匯聚在一起，重新定義帕金森氏症患者的照護。

深部腦部刺激（DBS）已從一項實驗性神經外科技術發展成為某些帕金森氏症患者的基石治療方法。本文概述了DBS開展的現代臨床、技術和系統背景。電極設計、刺激程序設定、影像整合和封閉回路型控制的進步，改變了人們對症狀改善、手術流程和長期設備管理的預期。同時，多學科診療模式正在革新圍手術全期護理流程，以最佳化患者選擇、降低併發症發生率並改善術後復健。為了應對這些趨勢並維持高品質的治療效果，醫院系統和專科診所需要重新評估人員配備、影像能力和神經調控管治。

對正在塑造當今 DBS 實踐的臨床方案、設備架構、報銷框架和以患者為中心的結果的變革性變化進行詳細的策略概述。

DBS領域正在經歷變革，其影響​​涵蓋臨床實踐、設備設計、醫保體係以及患者期望等各個方面。臨床上，人們越來越重視對合適的患者進行早期療育，這促使人們重新評估轉診途徑，並加強運動神經科神經科和功能性神經外科醫生之間的合作。技術創新是推動這項變革的主要動力。自適應控制模式和改進的電極結構能夠實現更個人化的刺激方案，進而影響手術標靶的選擇和術後程控策略。這些設備層面的進步正促使臨床醫師採用新的療效評估指標，不僅包括運動功能評分，還包括認知功能、自主神經功能和生活品質（QOL）。

對 2025 年美國關稅對 DBS 設備供應鏈、零件採購、採購成本和跨境製造的累積影響進行嚴格評估。

美國2025年實施的關稅對深部腦部刺激（DBS）生態系統產生了多方面的影響，波及成本結構、採購決策和製造地配置。依賴跨境供應導線、植入式脈衝產生器和配件的製造商面臨投入成本上升的困境，迫使他們重新評估供應商關係和庫存策略。為此，一些設備製造商加快了供應基地多元化的步伐，並探索近岸外包方案以降低貿易政策波動帶來的風險。同時，其他製造商則選擇承受短期成本上漲，以維持與醫療系統的合約價格。

詳細的細分見解解釋了技術、組件、最終用戶環境和分銷管道的差異如何影響 DBS 的臨床部署和商業策略。

本文從詳細的市場區隔觀點，揭示了技術選擇、組件架構、臨床環境和分銷模式如何影響DBS（深部腦部刺激）的普及趨勢和商業策略。基於技術，市場被分為兩類：「自適應」和「傳統」。自我調整設備進一步細分為運動回饋和神經回饋，這兩者在程式設計複雜性、追蹤頻率和證據生成要求方面存在顯著差異。專注於運動回饋的設備往往優先考慮與穿戴式裝置和感測器平台的整合，而神經回饋解決方案則需要更先進的訊號處理和封閉回路型檢驗來證明其臨床可靠性。

區域分析重點在於主要全球市場的不同監管環境、臨床引入途徑、報銷情況和競爭動態。

區域趨勢顯著影響著全球範圍內的臨床准入、監管互動和商業策略。在美洲，醫療保健系統日益重視整合式診療路徑、批量採購和基於結果的合約。這些優先事項有利於那些能夠展現強大的臨床管治支援和可預測服務模式的供應商。歐洲、中東和非洲（EMEA）的監管和報銷環境各不相同，各國的衛生技術評估（HTA）框架和採購慣例要求供應商制定區域性的證據策略和靈活的商業性安排。在該地區的部分市場，公共採購週期和報銷談判時間表要求供應商制定分階段的准入計劃，並與當地成熟的企業建立合作關係。亞太地區神經外科醫療領域發展迅速，公共和私人醫療投資不斷成長，監管路徑也多種多樣，因此，靈活的打入市場策略和戰略合作夥伴關係更具優勢。

本文檔概述了 DBS（基於資料庫的模擬）領域競爭差異化的關鍵公司層面評估，包括策略重點、研發投資、夥伴關係模式和市場進入方法。

DBS領域的公司策略體現了在技術重點、夥伴關係關係建構和實證醫學證據開發方面的明確選擇。一些公司透過專注於自適應刺激和封閉回路型系統的研發，優先考慮神經訊號分析和長期臨床檢驗，在臨床療效方面脫穎而出。另一些公司則投資於模組化組件系統，以簡化升級和維護，從而實現產品逐步改進，而無需進行系統整體更換。一些公司強調整合服務模式，將設備銷售和培訓、遠端程式設計平台以及結構化的後續追蹤流程相結合，以減少治療結果的差異性並加強客戶關係。

為 DBS 領域的行業領導者提供優先考慮的、可操作的建議，以加速臨床部署、降低供應鏈風險、影響政策並建立永續的商業性優勢。

產業領導者可以採取一系列切實可行的優先行動，加速DBS的臨床部署，增強供應鏈韌性，並建立永續的商業性優勢。首先，將設備開發與基於可衡量的、以患者為中心的療效指標和真實世界臨床績效指標的臨床證據規劃相結合，這些指標應能引起支付方和醫療保健系統的共鳴。其次，投資於模組化服務架構和培訓項目，以減少植入和編程方面的差異，從而提高不同中心療效的一致性。第三，透過引入雙重採購、區域倉儲和可預測的備件供應，重新設計供應鏈，最大限度地降低貿易政策波動和物流中斷帶來的風險。

一份高度透明的調查方法聲明，說明了構成 DBS 分析基礎的資料收集、一級和二級調查、三角測量方法和檢驗過程。

本分析的研究途徑結合了第一手資料和第二手資料、相關人員對話以及迭代檢驗，從而得出穩健且可重複的結論。第一手資料包括對臨床醫生、採購經理和醫療設備工程師的結構化訪談，從中獲得了關於手術流程、證據優先排序和營運限制的定性見解。二級資訊來源包括同行評審的臨床文獻、監管文件和醫療設備技術規範，從中獲得了關於技術趨勢和安全性能的背景資訊。透過對這些數據進行三角驗證，我們整合了不同的觀點，並突顯了不同臨床環境和地區之間的一致性模式。

簡明扼要地整合了戰略意義、剩餘風險、創新促進因素以及相關人員在塑造帕金森氏症治療中 DBS 的未來方向時需要考慮的下一步因素。

總之，本報告整合了技術創新、不斷發展的臨床實踐和不斷變化的商業性趨勢對深部腦部刺激（DBS）領域中相關人員的策略意義。自適應刺激和封閉回路型模式的進步正在為個人化醫療樹立新的標準，同時也提高了人們對實證醫學、臨床醫生培訓和上市後監測的期望。同時，價值鍊和政策的發展趨勢凸顯了製定穩健的籌資策略和靈活的商業模式的必要性。因此，那些能夠整合臨床專案開發、完善的實證計劃和靈活的營運結構的機構，將更有能力將創新轉化為永續的臨床和商業性價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：帕金森氏症深部腦部刺激市場：依技術分類

  • 自適應
    • 運動回饋
    • 神經回饋
  • 傳統的

第9章：巴金森氏症深部腦部刺激市場：依組件分類

  • 延長線
  • 植入式脈衝產生器
  • 帶領
  • 程式設計師

第10章：帕金森氏症深部腦部刺激市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章：帕金森氏症深部腦部刺激市場：依分銷管道分類

  • 直銷
  • 銷售夥伴網路

第12章：巴金森氏症深部腦部刺激市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：巴金森氏症深部腦部刺激市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：巴金森氏症深部腦部刺激市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國帕金森氏症深部腦部刺激療法市場

第16章：中國帕金森氏症深部腦部刺激療法市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Aleva Neurotherapeutics SA
  • Beijing PINS Medical Co., Ltd.
  • Bioinduction Ltd.
  • Boston Scientific Corporation
  • Deep Brain Innovations LLC
  • FHC, Inc.
  • Functional Neuromodulation Ltd.
  • Inomed Medizintechnik GmbH
  • Integer Holdings Corporation
  • LivaNova, plc
  • Magstim Company Ltd.
  • Medtronic plc
  • Neurology Solutions
  • NeuroMetrix, Inc.
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • Newronika Srl
  • Nuvectra Corporation
  • Renishaw plc
  • SceneRay Corporation Ltd.
  • Soterix Medical Inc.
  • Suzhou PINS Medical Co., Ltd.
  • Synapse Biomedical, Inc.
  • Zynex, Inc.
Product Code: MRR-A339DAEFA88E

The Deep Brain Stimulation in Parkinson's Disease Market was valued at USD 1.41 billion in 2025 and is projected to grow to USD 1.61 billion in 2026, with a CAGR of 16.15%, reaching USD 4.02 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.41 billion
Estimated Year [2026] USD 1.61 billion
Forecast Year [2032] USD 4.02 billion
CAGR (%) 16.15%

A comprehensive introduction establishing how advances in neuromodulation, multidisciplinary clinical pathways, and device innovation converge to redefine Parkinson's disease patient care

Deep brain stimulation has evolved from an experimental neurosurgical technique into a cornerstone intervention for selected patients with Parkinson's disease, and this introduction frames the contemporary clinical, technological, and system-level context in which DBS operates. Advances in electrode design, stimulation programming, imaging integration, and closed-loop control have altered expectations around symptomatic benefit, procedural workflows, and long-term device management. At the same time, multidisciplinary care models are shifting perioperative pathways to improve candidate selection, reduce complication rates, and optimize postoperative rehabilitation. These trends require hospital systems and specialty clinics to rethink staffing, imaging capacity, and neuromodulation governance to sustain high-quality outcomes.

Regulatory interaction and payer engagement are increasingly important as novel features and adaptive technologies emerge; manufacturers and clinical champions must now articulate value beyond symptom control to include quality-of-life metrics, reductions in medication burden, and downstream healthcare utilization. Supply chain resilience and device servicing models have likewise become operational priorities as institutions weigh in-house capabilities for battery replacements, programming follow-ups, and lead management. As a result, the contemporary introduction positions DBS not merely as a surgical device but as an integrated clinical program that intersects technology, care delivery, and commercial strategy.

An in-depth strategic overview of transformative shifts in clinical protocols, device architecture, reimbursement frameworks, and patient-centered outcomes shaping DBS practice today

The DBS landscape is undergoing transformative shifts that span clinical practice, device engineering, reimbursement ecosystems, and patient expectations. Clinically, greater emphasis on earlier intervention for well-selected patients is prompting revised referral pathways and heightened collaboration between movement disorder neurologists and functional neurosurgeons. Technological innovation has reinforced this shift: adaptive control paradigms and improved lead architectures are enabling more personalized stimulation profiles, which in turn influence surgical targeting and postoperative programming strategies. These device-level improvements are prompting clinicians to adopt outcome measures that extend beyond motor scores to incorporate cognitive, autonomic, and quality-of-life domains.

Concurrently, reimbursement and health technology assessment frameworks are evolving to accommodate real-world evidence and long-term outcome data. This change encourages manufacturers and health systems to co-develop evidence generation plans that demonstrate clinical and economic value. Supply chain and manufacturing strategies have shifted toward modularity and regionalization to reduce exposure to single-source disruptions and to accelerate time-to-market for software-enabled device updates. Patient expectations and digital engagement are also reshaping post-implant care: remote programming, telehealth follow-ups, and patient-reported outcome capture are accelerating adoption of hybrid care models. Collectively, these shifts are restructuring competitive dynamics and creating opportunities for strategic collaboration across clinical, technical, and commercial stakeholders.

A rigorous assessment of the cumulative impact of United States tariffs in 2025 on supply chains, component sourcing, procurement costs, and cross-border manufacturing for DBS devices

The introduction of tariffs in the United States in 2025 has exerted a multifaceted influence on the deep brain stimulation ecosystem, affecting cost structures, sourcing decisions, and the configuration of manufacturing footprints. Manufacturers reliant on cross-border supply of leads, implantable pulse generators, and ancillary components confronted increased input costs that necessitated reassessment of supplier relationships and inventory strategies. In response, some device producers accelerated diversification of their supply base and explored nearshoring options to mitigate exposure to trade policy volatility, while others absorbed short-term cost increases to sustain contractual pricing with health systems.

From a procurement perspective, hospitals and ambulatory surgical centers revisited device selection criteria to account for total cost of ownership, logistics complexity, and warranty or servicing arrangements. Group purchasing organizations and networked health systems intensified negotiations around long-term service contracts and spare-parts provisioning to manage operational risk. Regulatory and customs processing timelines also influenced lead times for new product introductions, prompting manufacturers to plan earlier submissions and engage in more proactive stakeholder communication. Over time, the tariff-driven adjustments reinforced the importance of resilient supply chain design, transparent cost modeling, and collaborative contracting between device suppliers and care providers.

A granular segmentation insight explaining how distinctions across technology, componentry, end-user settings, and distribution channels drive clinical adoption and commercial strategy in DBS

A granular segmentation perspective clarifies how technology choices, component architectures, clinical settings, and distribution models influence adoption dynamics and commercial strategy for DBS. Based on Technology, market is studied across Adaptive and Conventional. The Adaptive is further studied across Motion Feedback and Neural Feedback, which materially alters programming complexity, follow-up cadence, and evidence-generation requirements. Devices emphasizing motion feedback tend to prioritize integration with wearable and sensor platforms, whereas neural feedback solutions require more sophisticated signal processing and closed-loop validation to demonstrate clinical reliability.

Based on Component, market is studied across Extension, Implantable Pulse Generator, Lead, and Programmer, and each element carries distinct service, replacement, and regulatory considerations. Lead design evolution primarily influences targeting precision and chronic stability, while IPG advancements impact battery life, software capability, and remote-management features. Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, which differ in procedural volume, perioperative resources, and post-implant care pathways; high-volume tertiary centers often become centers of excellence that drive referral patterns, whereas specialty clinics may lead in long-term programming and follow-up. Based on Distribution Channel, market is studied across Direct Sales and Distribution Partner Networks, and these choices affect local clinical training, aftermarket service capability, and the speed of new technology adoption. Taken together, these segmentation lenses inform targeted go-to-market design, clinical evidence plans, and service delivery models that stakeholders should align with their strategic priorities.

A regionally focused analysis highlighting divergent regulatory environments, clinical adoption pathways, reimbursement landscapes, and competitive dynamics across major global markets

Regional dynamics create materially different pathways for clinical adoption, regulatory engagement, and commercial strategy across the global landscape. In the Americas, health systems increasingly focus on integrated care pathways, bundled procurement, and performance-based contracting; these priorities favor vendors that can demonstrate robust clinical governance support and predictable service models. Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement environment, where country-level health technology assessment frameworks and procurement customs require localized evidence strategies and flexible commercial arrangements. In several markets within this region, public procurement cycles and reimbursement negotiation timelines dictate phased entry plans and partnerships with established local players. Asia-Pacific offers a contrasting mix of rapidly expanding neurosurgical capacity, public and private healthcare investment, and diverse regulatory pathways that reward agile market entry tactics and strategic alliances.

Across these regions, clinical practice patterns, device servicing models, and patient referral behaviors differ, influencing which provider types become early adopters and how post-implant care is organized. Stakeholders must therefore design regional strategies that balance global product consistency with local regulatory adaptation and tailored clinician engagement. This approach reduces launch friction and aligns evidence generation with payer needs in each geography.

A critical company-level evaluation of strategic priorities, R&D investments, partnership models, and go-to-market approaches that define competitive differentiation within the DBS landscape

Company-level strategies in the DBS sector reflect distinct choices about technology focus, partnership orchestration, and evidence development. Some firms have concentrated R&D on adaptive stimulation and closed-loop systems, prioritizing neural signal analytics and longer-term clinical validation to differentiate on clinical responsiveness. Others have invested in modular component systems that simplify upgrades and servicing, enabling incremental product enhancements without full-system replacement. Several companies emphasize integrated service models that combine device sales with training, remote-programming platforms, and structured follow-up pathways to reduce variation in outcomes and strengthen customer relationships.

Partnership plays are also prominent, with collaborations spanning imaging providers, software analytics companies, and rehabilitation service vendors to create end-to-end clinical solutions. Commercial tactics range from direct engagement with tertiary centers to alliances with distribution partners that provide localized clinical education and aftermarket support. Intellectual property strategies and regulatory submissions reflect these choices: companies investing heavily in adaptive algorithms often follow longer, data-rich regulatory pathways, while those emphasizing hardware refinements pursue iterative clearances. Investors and corporate development teams evaluating vendor capabilities should weigh the alignment between product roadmaps, clinical evidence commitments, and the operational demands of scaling across varied healthcare settings.

A prioritized set of actionable recommendations for industry leaders to accelerate clinical adoption, derisk supply chains, influence policy, and build durable commercial advantage in DBS

Industry leaders can pursue a set of pragmatic, prioritized actions to accelerate clinical adoption, strengthen supply resilience, and create durable commercial advantage in DBS. First, align device development and clinical evidence plans around measurable patient-centered outcomes and real-world performance metrics that resonate with payers and health systems. Second, invest in modular service architectures and training programs that reduce variability in implantation and programming, thereby improving consistency of outcomes across centers. Third, reassess supply chain design to incorporate dual sourcing, regional warehousing, and predictable spare-part provisioning that minimize exposure to trade policy shifts and logistical disruptions.

Fourth, cultivate collaborative relationships with centers of excellence, movement disorder neurologists, and rehabilitation providers to co-develop multicenter evidence and to accelerate diffusion of best practices. Fifth, adopt flexible commercial models that include outcome-based contracting, extended warranties, and bundled services to address evolving payer expectations. Finally, prioritize interoperability and software update pathways that allow devices to evolve post-implant with validated firmware and remote programming capabilities. Implementing these recommendations concurrently strengthens clinical credibility, reduces operational risk, and positions organizations to capitalize on emerging opportunities within integrated care ecosystems.

A transparent research methodology statement describing data collection, primary and secondary engagement, triangulation methods, and validation processes underpinning the DBS analysis

The research approach underlying this analysis combined primary and secondary methods, stakeholder engagement, and iterative validation to ensure robust, reproducible conclusions. Primary inputs included structured interviews with clinicians, procurement leaders, and device engineers, which provided qualitative insights into procedural workflows, evidence priorities, and operational constraints. Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, and device technical specifications to contextualize technological trends and safety performance. These data streams were triangulated to reconcile divergent perspectives and to highlight consistent patterns across clinical settings and geographies.

Analytical frameworks focused on capability mapping, supply chain vulnerability assessment, and clinical pathway integration. Validation cycles involved peer review by independent clinicians and industry experts to test the plausibility of inferred strategic implications. Where appropriate, scenario analysis was used to examine the consequences of policy shifts, technological milestones, or supply interruptions. Overall, the methodology emphasized transparency, reproducibility, and stakeholder relevance, ensuring that the insights are actionable for executive leaders, clinical program directors, and commercial teams seeking to navigate the evolving DBS landscape.

A concise synthesis of strategic takeaways, residual risks, innovation levers, and next-step considerations for stakeholders shaping the future trajectory of DBS in Parkinson's care

The conclusion synthesizes the strategic implications of technological innovation, shifting clinical practice, and evolving commercial dynamics for stakeholders engaged in deep brain stimulation. Advances in adaptive stimulation and closed-loop paradigms are setting new benchmarks for individualized therapy, but they also raise expectations for evidence generation, clinician training, and post-market surveillance. Meanwhile, supply chain and policy developments have underscored the necessity of resilient sourcing strategies and responsive commercial models. Therefore, organizations that integrate clinical program development, robust evidence plans, and flexible operational architectures will be best positioned to convert innovation into sustained clinical and commercial value.

Risk management remains central: procedural complexity, reimbursement uncertainty, and regulatory heterogeneity can all delay adoption or constrain market entry if unaddressed. Conversely, well-executed partnerships, targeted regional strategies, and investment in long-term outcome measurement create defensible differentiation. Ultimately, the path forward requires coordinated action across R&D, clinical engagement, supply chain design, and commercial execution to realize the full potential of DBS for patients with Parkinson's disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Deep Brain Stimulation in Parkinson's Disease Market, by Technology

  • 8.1. Adaptive
    • 8.1.1. Motion Feedback
    • 8.1.2. Neural Feedback
  • 8.2. Conventional

9. Deep Brain Stimulation in Parkinson's Disease Market, by Component

  • 9.1. Extension
  • 9.2. Implantable Pulse Generator
  • 9.3. Lead
  • 9.4. Programmer

10. Deep Brain Stimulation in Parkinson's Disease Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Deep Brain Stimulation in Parkinson's Disease Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distribution Partner Networks

12. Deep Brain Stimulation in Parkinson's Disease Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Deep Brain Stimulation in Parkinson's Disease Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Deep Brain Stimulation in Parkinson's Disease Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Deep Brain Stimulation in Parkinson's Disease Market

16. China Deep Brain Stimulation in Parkinson's Disease Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Aleva Neurotherapeutics SA
  • 17.7. Beijing PINS Medical Co., Ltd.
  • 17.8. Bioinduction Ltd.
  • 17.9. Boston Scientific Corporation
  • 17.10. Deep Brain Innovations LLC
  • 17.11. FHC, Inc.
  • 17.12. Functional Neuromodulation Ltd.
  • 17.13. Inomed Medizintechnik GmbH
  • 17.14. Integer Holdings Corporation
  • 17.15. LivaNova, plc
  • 17.16. Magstim Company Ltd.
  • 17.17. Medtronic plc
  • 17.18. Neurology Solutions
  • 17.19. NeuroMetrix, Inc.
  • 17.20. NeuroPace, Inc.
  • 17.21. NeuroSigma, Inc.
  • 17.22. Newronika S.r.l.
  • 17.23. Nuvectra Corporation
  • 17.24. Renishaw plc
  • 17.25. SceneRay Corporation Ltd.
  • 17.26. Soterix Medical Inc.
  • 17.27. Suzhou PINS Medical Co., Ltd.
  • 17.28. Synapse Biomedical, Inc.
  • 17.29. Zynex, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 105. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 106. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 123. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 124. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 129. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 130. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)